Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06362252 · ClinicalTrials.gov registry record · Phase 1

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 1
Development phase
123
Enrollment target
20
Study locations

NCT06362252 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 123 participants, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06362252, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 1
Development phase
123 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Atezolizumab
  • DRUG Ifinatamab deruxtecan

Study Locations (20)

New York

  • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone - Mineola
  • NYU Langone Hospital - Long Island - Mineola
  • Memorial Sloan Kettering Cancer Center - New York
  • Columbia University Hervert Irving Comprehensive Cancer Center - New York
  • Montefiore Medical Center - New York

Florida

  • Mayo Clinic-Jacksonville - Jacksonville
  • Advent Health Orlando - Orlando
  • Moffitt Cancer Center - Tampa

California

  • David Geffen School of Medicine - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach

Minnesota

  • Regents of the University of Minnesota - Minneapolis
  • Mayo Clinic - Rochester

New Jersey

  • Astera Cancer Care - East Brunswick
  • John Theurer Cancer Center At Hackensack Umc - Hackensack

Alabama

  • University of Alabama -Birmingham - Birmingham

Arizona

  • Mayo Clinic Arizona - Phoenix

Illinois

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2024-07-22
Est. Completion 2026-12-30
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06362252

The ClinicalTrials.gov registry entry for NCT06362252 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (28% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT06362252 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, Florida, California.

Frequently Asked Questions

What is clinical trial NCT06362252 about?

NCT06362252 is a clinical study titled "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)". This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

What is the current status of trial NCT06362252?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2024-07-22. Estimated completion is 2026-12-30.

What conditions does trial NCT06362252 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT06362252?

The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Ifinatamab deruxtecan (DRUG).

Who is sponsoring clinical trial NCT06362252?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06362252 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.